These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 12582420)

  • 1. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function.
    Lerner AM; Beqaj SH; Deeter RG; Dworkin HJ; Zervos M; Chang CH; Fitzgerald JT; Goldstein J; O'Neill W
    Drugs Today (Barc); 2002 Aug; 38(8):549-61. PubMed ID: 12582420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.
    Lerner AM; Beqaj SH; Deeter RG; Fitzgerald JT
    In Vivo; 2007; 21(5):707-13. PubMed ID: 18019402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients.
    Ozçay F; Arslan H; Bilezikçi B; Sevmiş S; Moray G; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2878-80. PubMed ID: 19765462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome.
    Lerner AM; Beqaj SH; Deeter RG; Fitzgerald JT
    In Vivo; 2004; 18(2):101-6. PubMed ID: 15113035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers.
    Hoshino Y; Katano H; Zou P; Hohman P; Marques A; Tyring SK; Follmann D; Cohen JI
    J Virol; 2009 Nov; 83(22):11857-61. PubMed ID: 19740997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody to Epstein-Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset.
    Lerner AM; Ariza ME; Williams M; Jason L; Beqaj S; Fitzgerald JT; Lemeshow S; Glaser R
    PLoS One; 2012; 7(11):e47891. PubMed ID: 23155374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi.
    Olson D; Gulley ML; Tang W; Wokocha C; Mechanic O; Hosseinipour M; Gold SH; Nguluwe N; Mwansambo C; Shores C
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):112-8. PubMed ID: 23260601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valtrex therapy for Epstein-Barr virus reactivation and upper respiratory symptoms in elite runners.
    Cox AJ; Gleeson M; Pyne DB; Saunders PU; Clancy RL; Fricker PA
    Med Sci Sports Exerc; 2004 Jul; 36(7):1104-10. PubMed ID: 15235312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-barr Virus and/or cytomegalovirus in patients with chronic fatigue syndrome.
    Lerner AM; Dworkin HJ; Sayyed T; Chang CH; Fitzgerald JT; Beqaj S; Deeter RG; Goldstein J; Gottipolu P; O'Neill W
    In Vivo; 2004; 18(4):417-24. PubMed ID: 15369178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valacyclovir treatment of chronic fatigue in adolescents.
    Henderson TA
    Adv Mind Body Med; 2014; 28(1):4-14. PubMed ID: 24445302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to valacyclovir in an HIV-infected girl with Epstein Barr infection.
    Shah I
    Indian Pediatr; 2012 May; 49(5):409-10. PubMed ID: 22700667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical symptoms and markers of disease mechanisms in adolescent chronic fatigue following Epstein-Barr virus infection: An exploratory cross-sectional study.
    Kristiansen MS; Stabursvik J; O'Leary EC; Pedersen M; Asprusten TT; Leegaard T; Osnes LT; Tjade T; Skovlund E; Godang K; Wyller VBB
    Brain Behav Immun; 2019 Aug; 80():551-563. PubMed ID: 31039432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
    Simon MW; Fish DN; Deeter RG
    Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of the Epstein-Barr virus on the nervous system].
    Kononenko VV
    Lik Sprava; 2001; (4):107-11. PubMed ID: 11692687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue.
    Kogelnik AM; Loomis K; Hoegh-Petersen M; Rosso F; Hischier C; Montoya JG
    J Clin Virol; 2006 Dec; 37 Suppl 1():S33-8. PubMed ID: 17276366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir.
    Walling DM; Flaitz CM; Nichols CM
    J Infect Dis; 2003 Sep; 188(6):883-90. PubMed ID: 12964120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.
    Montoya JG; Kogelnik AM; Bhangoo M; Lunn MR; Flamand L; Merrihew LE; Watt T; Kubo JT; Paik J; Desai M
    J Med Virol; 2013 Dec; 85(12):2101-9. PubMed ID: 23959519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers.
    Watt T; Oberfoell S; Balise R; Lunn MR; Kar AK; Merrihew L; Bhangoo MS; Montoya JG
    J Med Virol; 2012 Dec; 84(12):1967-74. PubMed ID: 23080504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis.
    Vezina HE; Balfour HH; Weller DR; Anderson BJ; Brundage RC
    J Clin Pharmacol; 2010 Jul; 50(7):734-42. PubMed ID: 19897764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study.
    Leruez-Ville M; Ghout I; Bussières L; Stirnemann J; Magny JF; Couderc S; Salomon LJ; Guilleminot T; Aegerter P; Benoist G; Winer N; Picone O; Jacquemard F; Ville Y
    Am J Obstet Gynecol; 2016 Oct; 215(4):462.e1-462.e10. PubMed ID: 27083761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.